Anticoagulation and Antiplatelet Agent Resumption Timing fo
10.13004/kjnt.2023.19.e42
- Author:
In-Ho JUNG
1
;
Jung-Ho YUN
;
Sung Jin KIM
;
Jaewoo CHUNG
;
Sang Koo LEE
Author Information
1. Department of Neurosurgery, Dankook University College of Medicine, Cheonan, Korea
- Publication Type:Review Article
- From:Korean Journal of Neurotrauma
2023;19(3):298-306
- CountryRepublic of Korea
- Language:English
-
Abstract:
Traumatic brain injury (TBI) is a major global health concern. Due to the increase in TBI incidence and the aging population, an increasing number of patients with TBI are taking antithrombotic agents for their underlying disease. When TBI occurs in patients with these diseases, there is a conflict between the disease, which requires an antithrombotic effect, and the neurosurgeon, who must minimize intracranial hemorrhage. Nevertheless, there are no clear guidelines for the reversal or resumption of antithrombotic agents when TBI occurs in patients taking antithrombotic agents. In this review article, we intend to classify antithrombotic agents and provide information on them. We also share previous studies on the reversal and resumption of antithrombotic agents in patients with TBI to help neurosurgeons in this dilemma.
